Betaine | Jotup

NUNORM LAUNCHES MEN'S MAKEUP LINE CREATING INCLUSIVE BEAUTY FOR EVERYONE

Retrieved on:

Thursday, January 11, 2024

Olive, Woman, Squalane, Face, Perception, Olive oil, Oil, Betaine, Head, Skin, Perspiration, Masculinity, Red, Hyaluronic acid, Acne, Cosmetics

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- A new line of makeup specifically formulated for men's skin, NuNorm, announces the launch of the core collection today. Founded by Jeff Lau, NuNorm offers five innovative products that are found to be the most essential in a man's daily routine. Recognizing the lack of makeup products tailored to men, Jeff's vision for NuNorm is to break the stigma and empower every man to live more authentically and to present the best version of themselves while caring for their own skin.

Key Points:

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- A new line of makeup specifically formulated for men's skin, NuNorm , announces the launch of the core collection today.
Founded by Jeff Lau, NuNorm offers five innovative products that are found to be the most essential in a man's daily routine.
"Regardless of gender, we want to change the outdated perception that is exclusively for women and help men feel empowered with high-quality makeup products catered to them," says Jeff.
Consumers can find the ideal shade using the mobile device camera to virtually try each shade and swipe for the perfect match instantly.

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

Retrieved on:

Thursday, November 9, 2023

NDA, Betaine, Carglumic acid, Nitisinone, Administration, Patient, Research, FDA, Marketing, Hand, R, Research and development, Growth, Hydrocortisone, Pharmaceutical industry, Video game

Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growth

Key Points:

Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growth
Generated $0.9 million in positive cash flow from operations; ended quarter with $22.1 million of cash on hand
DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2023.
Eton reported third quarter 2023 product sales and royalty revenue of $7.0 million, representing 118% growth over the prior year period and 8% growth over the second quarter of 2023.
Product sales and royalty revenue for the third quarter of 2023 were up 8% over the second quarter of 2023.
As previously announced, Eton will host its third quarter 2023 conference call as follows:

Designs for Health Launches Innovative Probiotic Toothpaste, PerioBiotic™ Silver

Retrieved on:

Monday, November 6, 2023

PALM COAST, Fla., Nov. 6, 2023 /PRNewswire/ -- Designs for Health, the expert-recommended and preferred brand for high-quality, professional strength, research-backed supplements, and recipient of the 2023 Top Nutraceutical Company award** today announced the launch of PerioBiotic™ Silver, a fluoride-free probiotic toothpaste formulated with a unique combination of ingredients to support tooth enamel strength, brighten your smile, and support overall oral health.* This product joins Designs for Health's growing line of oral health solutions including PerioPull™ and Periommune™.

Key Points:

* This product joins Designs for Health's growing line of oral health solutions including PerioPull™ and Periommune™ .
* Similar to the role of probiotics in the gastrointestinal tract, beneficial oral bacteria may help maintain dental and oral health.
Purified silver may support overall oral wellness, CoQ10 may help support gum health, and grape seed extract may help healthy inflammatory support.
To learn more about Designs for Health and its comprehensive portfolio of products, including its line of oral health products, visit https://www.designsforhealth.com .

Serious Concerns About Frequent Heartburn Medications Spurs Demand for Healthy Alternatives

Retrieved on:

Thursday, October 26, 2023

VENICE, Fla., Oct. 26, 2023 /PRNewswire/ -- As consumer interest in heartburn solutions reaches unprecedented levels, Enzymedica, a trusted leader in digestive health, introduces a range of all-natural, healthy alternatives for occasional heartburn and indigestion relief. This move comes in response to the recent revelation of a study linking long-term usage of Proton Pump Inhibitors (PPIs) to potential health risks, including dementia. With a commitment to providing safe and effective solutions, Enzymedica offers consumers a variety of options that not only relieve symptoms of occasional heartburn resulting from food and diet choices, but also promote overall digestive wellness.

Key Points:

VENICE, Fla., Oct. 26, 2023 /PRNewswire/ -- As consumer interest in heartburn solutions reaches unprecedented levels, Enzymedica , a trusted leader in digestive health, introduces a range of all-natural, healthy alternatives for occasional heartburn and indigestion relief.
The heartburn solutions category has faced stagnation due to a lack of innovation, concerns about drug side effects and confusion surrounding the frequent, long-term usage of PPIs and other acid inhibitors.
The recent study shedding light on potential health risks associated with PPIs has left consumers seeking trustworthy alternatives that prioritize their well-being.
These products offer consumers a reliable and convenient way to address their occasional heartburn concerns with natural, science-backed solutions.

Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on:

Thursday, August 10, 2023

Lamotrigine, Betaine, NDA, Hydrocortisone, Trimethylglycine, Carglumic acid, Sale, Eton, Acquisition, Patient, Administration, Growth, Research and development, R, Rare, Research, FDA, Pharmaceutical industry, Video game

DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2023.

Key Points:

DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2023.
Eton reported second quarter 2023 product sales and royalty revenue of $6.5 million, representing 175% growth over the prior year period and 22% growth over the first quarter of 2023.
Net Revenue: Net sales for the second quarter of 2023 were $12.0 million compared with $7.4 million in the prior year period.
As previously announced, Eton will host its second quarter 2023 conference call as follows:

Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

Retrieved on:

Wednesday, May 31, 2023

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU). In this cohort, five patients were randomized in a blinded fashion to receive 2.5 mg/kg of lyophilized pegtibatinase or placebo twice weekly (BIW), with four patients assigned to the treatment group. In this highest dose cohort to date, treatment with pegtibatinase resulted in rapid and sustained reductions in total homocysteine (tHcy), with a 67.1% mean relative reduction in tHcy from baseline, as well as maintenance of mean tHcy below the clinically meaningful threshold of 100 μM, over weeks 6 to 12. To date in the study, pegtibatinase has been generally well-tolerated.

Key Points:

ET
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU).
The Company plans to present additional detailed study results at an upcoming medical meeting or in a peer-reviewed publication.
ET to discuss the topline results from cohort 6 in the Phase 1/2 COMPOSE Study.
Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.

Eton Pharmaceuticals Reports First Quarter 2023 Financial Results

Retrieved on:

Thursday, May 11, 2023

Endocrinology, Betaine, Carglumic acid, Eton, Adrenal insufficiency, Patient, Administration, Growth, Research and development, R, Rare, Research, Disease, Pharmaceutical industry, Video game, G&A

DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2023.

Key Points:

DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2023.
Eton reported first quarter 2023 product sales and royalty revenue of $5.3 million, representing 144% growth over the prior year period and 52% growth over the fourth quarter of 2022.
The first quarter results benefited from key account conversions that the company believes are a direct result of its expanded sales team.
As previously announced, Eton Pharmaceuticals will host its first quarter 2023 conference call as follows:

Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)

Retrieved on:

Wednesday, May 10, 2023

DEER PARK, Ill., May 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the commercial availability of Betaine Anhydrous for Oral Solution 180 grams for the treatment of homocystinuria.

Key Points:

“We are excited to be offering a lower cost alternative1 to Cystadane while still providing full patient and provider support services.
Betaine Anhydrous is available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions.
Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals.
Betaine anhydrous for oral solution is indicated in children and adults for the treatment of homocystinuria to decrease high homocysteine blood levels.

Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results

Retrieved on:

Thursday, March 16, 2023

DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022.

Key Points:

DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022.
Eton reported fourth quarter 2022 product sales and royalty revenue of $3.5 million, representing 220% growth over the prior year and 9% growth over the third quarter of 2022.
The Company expects the sequential growth rate to increase in the first quarter of 2023 compared to the fourth quarter of 2022.
As previously announced, Eton Pharmaceuticals will host a its fourth quarter 2022 conference call as follows:

Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)

Retrieved on:

Thursday, March 2, 2023

Biotechnology, Pharmaceutical, Health, Homocysteine, Medication, Oral, Betaine, Multimedia, Homocystinuria, Full, Use, Patient, NDC, Pharmaceutical industry

Cosette Pharmaceuticals, Inc. ("Cosette") has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (“Betaine”) in an agreement with ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) and commenced shipping (NDC #0713-0352-81) to customers this week.

Key Points:

Cosette Pharmaceuticals, Inc. ("Cosette") has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (“Betaine”) in an agreement with ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) and commenced shipping (NDC #0713-0352-81) to customers this week.
This press release features multimedia.
This launch will provide patients with homocystinuria, and the healthcare providers delivering care to those patients, with a safe, efficacious and accessible treatment option.
See the Full Prescribing Information and Instructions for Use for Betaine Anhydrous for Oral Solution, 180 grams.